|
|
|
|
| LEADER |
06240nam a2200361 u 4500 |
| 001 |
EB001840442 |
| 003 |
EBX01000000000000001004431 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 100 |
1 |
|
|a Feltner, Cynthia
|
| 245 |
0 |
0 |
|a Serological screening for genital herpes
|h Elektronische Ressource
|b an evidence review for the U.S. Preventive Services Task Force
|c prepared by RTI International-University of North Carolina Evidence-based Practice Center ; investigators, Cynthia Feltner, Catherine Grodensky, Charles Ebel, Jennifer Cook Middleton, Russell P. Harris, Mahima Ashok, Daniel E. Jonas
|
| 260 |
|
|
|a Rockville, MD
|b Agency for Healthcare Research and Quality
|c 2016, December 2016
|
| 300 |
|
|
|a 1 PDF file (x, 88 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Herpes Genitalis / diagnosis
|
| 653 |
|
|
|a False Positive Reactions
|
| 653 |
|
|
|a Serologic Tests / adverse effects
|
| 653 |
|
|
|a Asymptomatic Infections
|
| 710 |
2 |
|
|a RTI International-University of North Carolina Evidence-based Practice Center
|
| 710 |
2 |
|
|a United States
|b Agency for Healthcare Research and Quality
|
| 710 |
2 |
|
|a U.S. Preventive Services Task Force
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Evidence synthesis
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK409117
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a PURPOSE: To assess the benefits and harms of serologic screening and preventive interventions for genital herpes simplex virus (HSV) infection in asymptomatic adults, adolescents, and pregnant women. DATA SOURCES: PubMed/MEDLINE, the Cochrane Library, EMBASE, and trial registries through March 31, 2016 and reference lists of retrieved articles; outside experts; reviewers; and surveillance of literature through October 31, 2016. STUDY SELECTION: Two investigators independently selected English-language studies using a priori criteria.
|
| 520 |
|
|
|a Eligible studies included randomized, controlled trials (RCTs) of screening or preventive interventions for genital HSV infection, RCTs assessing the benefits or harms of preventive interventions aimed at reducing transmission or future symptomatic episodes of genital herpes, studies evaluating accuracy of serologic screening tests for HSV-2, systematic reviews (and studies published after eligible systematic reviews) evaluating the accuracy of serologic tests or harms of screening, multi-institution antiviral medication pregnancy exposure registries, and trials or observational studies assessing the harms of serologic screening. DATA EXTRACTION: One investigator extracted data and a second checked accuracy. Two reviewers independently rated quality for all included studies using predefined criteria. DATA SYNTHESIS: We included 17 studies. No RCTs compared screening with no screening.
|
| 520 |
|
|
|a Two RCTs compared preventive antiviral medications with placebo among serodiscordant couples to prevent HSV-2 transmission; these studies were heterogeneous and found inconsistent results. LIMITATIONS: Most studies assessing the accuracy of serologic screening tests were conducted in African countries where the prevalence of HSV-2 is much higher than in the United States. The true prevalence of asymptomatic HSV-2 infection in the United States is unknown. We identified no eligible studies that assessed behavioral counseling interventions in adults, adolescents, or pregnant women with asymptomatic or unrecognized genital herpes. Two RCTs assessing preventive antiviral medications in populations with asymptomatic HSV-2 were heterogeneous and followed participants over a short time (6 to 8 weeks).
|
| 520 |
|
|
|a Eleven studies assessed the accuracy of one or more serologic tests for HSV-2; most of these 11 studies enrolled populations with a high prevalence of HSV-2 (>40%) and did not describe whether participants had current or past symptoms consistent with genital herpes. Ten studies assessing the accuracy of the HerpeSelect(r) HSV-2 test (n=6,537 participants) provided sufficient data to estimate sensitivity and specificity at the manufacturer's cutpoint (1.1); pooled estimates of sensitivity and specificity were 99 percent (95% CI, 97 to 100) and 81 percent (95% CI, 68 to 90), respectively. Seven studies (n=5,516 participants) also assessed the accuracy of HerpeSelect at higher cutpoints (ranging from 2.2 to 3.5); pooled estimates of sensitivity and specificity were 95 percent (95% CI, 91 to 97) and 89 percent (95% CI, 82 to 93), respectively.
|
| 520 |
|
|
|a Two RCTs assessing preventive antiviral medications in serodiscordant couples were heterogeneous; one enrolled generally healthy couples who were serodiscordant for both HSV-2 and HIV from African countries. CONCLUSIONS: Serologic screening tests are associated with a high rate of false-positive results in populations with a HSV-2 prevalence similar to that in the U.S. adult population. Serologic screening for genital herpes is associated with potential psychosocial harms, including distress and anxiety. Current evidence from controlled trials does not establish whether or not preventive antiviral medication for asymptomatic HSV-2 infection has benefit
|
| 520 |
|
|
|a Four studies (n=1,512 participants) evaluated the accuracy of the Biokit HSV-2 Rapid Test; pooled estimates of sensitivity and specificity were 84 percent (95% CI, 73 to 91) and 95 percent (95% CI, 93 to 97), respectively. Use of HerpeSelect at the manufacturer's cutpoint in a population of 100,000 with a HSV-2 prevalence of 16 percent (the seroprevalence in the general U.S. adult population with unknown symptom status) would result in 15,840 true-positive tests and 15,960 false-positive tests (positive predictive value, 50%). Serologic screening for genital herpes is associated with psychosocial harms, including distress and anxiety related to positive test results. Two RCTs compared preventive antiviral medications with placebo in nonpregnant adults who were HSV-2 seropositive and reported on symptoms consistent with genital herpes over 6 to 8 weeks; these studies found inconsistent results.
|